|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||||||
| Current assets: | |||||||||||||||||
| Cash | |||||||||||||||||
| Prepaid expenses and other current assets | |||||||||||||||||
| Australia research and development incentives receivable | |||||||||||||||||
| Total current assets | |||||||||||||||||
| Deferred offering costs | |||||||||||||||||
| Other assets | |||||||||||||||||
| Total assets | |||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||||||||
| Current liabilities: | |||||||||||||||||
| Accounts payable | |||||||||||||||||
| Accrued expenses | |||||||||||||||||
| Total current liabilities | |||||||||||||||||
| Long term liabilities: | |||||||||||||||||
| Warrant liability | |||||||||||||||||
| Warrant liability | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||
| Common stock, $0.0001 par value, 150,000,000 shares authorized at June 30, 2026 and at December 31, 2025, respectively, 60,817,482 and 38,624,289 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | |||||||||||||||||
| Additional paid-in capital | |||||||||||||||||
| Accumulated deficit | |||||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||||
| Total stockholders’ equity | |||||||||||||||||
| Total liabilities and stockholders’ equity |
Loading...
